Head & Neck Cancers | Specialty

Multikinase TKIs for NSCLC and Medullary Thyroid Cancer

October 18th 2019

RET Fusion, Point Mutation, and Signaling

October 18th 2019

Why RET Alteration is an Attractive Target for Therapy

October 18th 2019

Dr. Bourhis on the Rationale to Explore Debio 1143 in Head and Neck Cancer

October 17th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the rationale to explore Debio 1143 in patients with head and neck cancer.

Dr. Gross on Neoadjuvant Cemiplimab in Head and Neck CSCC

October 12th 2019

Neil D. Gross, MD, FACS, discusses a phase II study of neoadjuvant cemiplimab in patients with stage III/IV cutaneous squamous cell carcinoma of the head and neck.

Dr. Saba Discusses Ongoing Research in Head and Neck Cancer

October 11th 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses ongoing research in head and neck cancer.

Dr. Bourhis on Results of the Phase II Trial With Debio 1143 in Head and Neck Cancer

October 10th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the results of a phase II trial evaluating the addition of Debio 1143 to concurrent high-dose cisplatin and chemoradiation in high-risk patients with locally advanced squamous cell carcinoma of the head and neck.

Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected

September 29th 2019

The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.

OncLive Community Discussion to Center on De-Intensification Strategies in OPSCC

September 9th 2019

The question of what the accepted therapeutic strategies for de-intensification in low-risk, HPV-related oropharyngeal squamous cell carcinoma are will be debated in an upcoming discussion.

Molecular Testing Enhances Decision-Making Process in Thyroid Cancer of Indeterminate Malignancy

September 7th 2019

In thyroid cancer, molecular diagnostic tests enable oncologists to evaluate thyroid nodules with atypical, suspicious, or indeterminate fine-needle aspiration cytology to determine the best course of treatment based on cytopathological result.

Metformin Plus Chemoradiation Induces Antitumorigenic Immune Response in HNSCC

September 6th 2019

Vidhya Karivedu, MD, fellow/resident at the University of Cincinnati College of Medicine, discusses the antitumorigenic immune response seen with the combination of metformin and chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.

Data Show Potential Impact of Shared Decision Making With RAI Therapy in Thyroid Cancer

August 29th 2019

Patients with differentiated thyroid cancer who were felt to not have a choice in receiving radioactive iodine treatment reportedly had lower satisfaction with the treatment decision, suggesting a need for increased shared decision making between physicians and patients.

Study Suggests Role for Anti-PD-1/PD-L1 Agents in Advanced Thyroid Cancer

August 29th 2019

Among patients with medullary thyroid cancer, PD-L1 positive status is linked to more aggressive clinicopathological features and predictive of structural and biochemical recurrences.

Dr. Burtness on the Future of Immunotherapy in Head and Neck Cancer

August 29th 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the future of immunotherapy in head and neck cancer.

Dr. Saba on Investigational Deintensification Approaches in HPV-Related HNSCC

August 15th 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses investigational deintensification approaches in HPV-related oropharyngeal squamous cell carcinoma.

Dr. Saba on Treatment Deintensification in HPV-Related Oropharyngeal Squamous Cell Carcinoma

August 1st 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses treatment deintensification for patients with HPV-related oropharyngeal squamous cell carcinoma.

Dr. Rischin on KEYNOTE-048 Results in Head and Neck Squamous Cell Carcinoma

August 1st 2019

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the phase III KEYNOTE-048 trial, which examines pembrolizumab or pembrolizumab plus chemotherapy versus EXTREME as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Saba on Improving Cancer Detection Rates in HNSCC

June 27th 2019

Nabil F. Saba, MD, FACP, discussed the role of general practitioners in maintaining the health of their patients with cancer and how to better diagnosis select types of head and neck cancer.

FDA Approves Single-Agent Pembrolizumab or Plus Chemo for Frontline HNSCC

June 11th 2019

The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma as monotherapy whose tumors express PD-L1 (composite positive score [CPS] ≥1) and also in combination with platinum and fluorouracil (FU) for this patient population, irrespective of PD-L1 expression.

ASCO 2019: Dr. Plimack Highlights Practice-Changing Data for Genitourinary Cancers

June 2nd 2019